Metastatic Prostate Cancer suffers have good news.  Xofigo, also known as Radium-223 (Ra-223), is a treatment for patients with castration-resistant prostate cancer (CRPC) and symptomatic (you can feel them) bone metastases (mets).  Early results of an international, open-label, phase 1/2 study (NCT01934790) showed that re-treating pts with Ra-223 was well tolerated with favorable effects on disease progression.  You can also be on abiraterone, enzalutamide at the same time. There were no serious drug-related problems for the 44 patients in this study.  This study should give you and your oncologist more confidence that you can have two rounds of Xofigo fo